BusinessActinium Pharmaceuticals to Present at 19th Annual Bio€quity Europe Conference in Ghent, BelgiumBy Nasdaq OMXMay 8, 2018, 11:30 AM UTC
BusinessActinium Pharmaceuticals Appoints Dr. Jeffrey Chell, Bone Marrow Transplant Visionary and Chief Executive Officer Emeritus of Be The Match and National Marrow Donor Program, to its Board of DirectorsBy Nasdaq OMXMay 1, 2018, 11:31 AM UTC
BusinessActinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical DevelopmentBy Nasdaq OMXApr 18, 2018, 11:30 AM UTC
BusinessGeneTx Biotherapeutics receives FDA orphan-drug designation for Angelman syndrome treatmentBy Nasdaq OMXMar 27, 2018, 5:26 PM UTC
BusinessActinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AMLBy Nasdaq OMXMar 13, 2018, 11:30 AM UTC
BusinessActinium Pharmaceuticals Announces Commencement of Rights Offering Subscription PeriodBy Nasdaq OMXFeb 22, 2018, 12:31 PM UTC
BusinessActinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AMLBy Nasdaq OMXFeb 12, 2018, 9:15 PM UTC
BusinessActinium Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of RecordBy Nasdaq OMXFeb 12, 2018, 12:30 PM UTC
